Ceritinib in ALK-rearranged non-small-cell lung cancer
Carcinoma, Non-Small-Cell Lung
Drug Resistance, Neoplasm
Protein Kinase Inhibitors
Receptor Protein-Tyrosine Kinases
Ceritinib was highly active in patients with advanced, ALK-rearranged NSCLC, including those who had had disease progression during crizotinib treatment, regardless of the presence of resistance mutations in ALK. (Funded by Novartis Pharmaceuticals and others; ClinicalTrials.gov number, NCT01283516.).